ProMIS Neurosciences (PMN) vs Rallybio (RLYB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Rallybio (RLYB) has outperformed ProMIS Neurosciences (PMN) over the past year, gaining 268.7% versus a loss of 35.8%. Over five years, RLYB leads with a -86.3% price change compared with -95.9% for PMN. Rallybio is the larger company by market cap ($90.0 million vs $86.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PMN | RLYB |
|---|---|---|
| Share price | $9.61 | $16.95 |
| Market cap | $86.18M | $90.05M |
| 1-day change | +5.03% | -0.23% |
| YTD return | +33.97% | +209.58% |
| 1-year return | -35.79% | +268.71% |
| 5-year return | -95.93% | -86.32% |
| P/E ratio (TTM) | — | 2.12 |
| EPS (TTM) | $-11.65 | $8.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $27.40 | $17.57 |
| 52-week low | $6.27 | $3.67 |
| Distance from 52-week high | -64.93% | -3.55% |
| Analyst consensus | none | — |
| Avg. price target upside | +343.39% | — |
| Average volume | 83.76K | 21.33K |
| Shares outstanding | 8.97M | 5.31M |
| Employees | 10 | 7 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RLYB has outperformed PMN by 304.5 percentage points over the past year.
About ProMIS Neurosciences
PMN stock →ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada.
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
About Rallybio
RLYB stock →Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
PMN vs RLYB FAQ
Which is bigger, ProMIS Neurosciences or Rallybio?
Rallybio (RLYB) is larger, with a market capitalization of $90.05M compared with $86.18M for ProMIS Neurosciences (PMN).
Which stock has performed better over the past year, PMN or RLYB?
RLYB returned +268.71% over the past 12 months, compared with -35.79% for PMN (price return, excluding dividends). Past performance does not predict future results.
Are ProMIS Neurosciences and Rallybio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.